



TOUJEO™:

Administered with a prefilled pen

TOUJEO™ is indicated for once-daily subcutaneous administration in the treatment of adult patients (≥ 18 years) with Type 1 or Type 2 diabetes mellitus who require basal (long-acting) insulin for glycemic control¹

TOUJEO™ [insulin glargine 300 units/mL] is available in the TOUJEO™ SoloSTAR® disposable prefilled pen (450 U/1.5 mL)¹

To avoid dosing errors and potential overdose, TOUJEO™ must never be drawn from the cartridge of the prefilled pen into a syringe¹



Standard insulin syringes are graduated for 100 U/mL of insulin, but the TOUJEO™ SoloSTAR® pen contains 300 U/mL¹

The dose pointer of the TOUJEO™ SoloSTAR® disposable prefilled pen shows the number of units of TOUJEO™ to be injected¹

The TOUJEO™ SoloSTAR® pen has been specifically designed for TOUJEO™, so no dose re-calculation is required¹

- Prior to initiation of TOUJEO™, train patients on proper use and injection technique¹
- Training reduces the risk of administration errors such as needle sticks and incomplete dosing¹
- Remind patients to follow the "Instructions for Use" to correctly use the pen device and administer TOUJEO™¹


Please consult the Product Monograph at <http://products.sanofi.ca/en/toujeo-solostar.pdf> for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph may also be obtained by calling 1.888.852.6887.

Reference: 1. TOUJEO™ SoloSTAR® Product Monograph, Sanofi Canada Inc., May 28, 2015.

Copyright © 2016 sanofi-aventis Canada Inc. All rights reserved.

SANOFI DIABETES 

MEMBER OF INNOVATIVE MEDICINES CANADA 
CDN.TOU.16.11.06E 50123065


Toujeo™
insulin glargine 300 U/mL